Abstract
PP215 Differential efficacy of tyrosine kinase inhibitors (TKIs) according to the type of EGFR activating mutations and agents in non-small cell lung cancer (NSCLC): A real-world study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have